Trial ID or NCT#
NCT02341560
Status
NOT RECRUITING
Purpose
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI-1007.
Official Title
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Eligibility Criteria
Ages Eligible for Study: 50 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Theodore Leng, MD, FACS
Ophthalmologist
Associate Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)
Shannon Beres, MD
Neuro-ophthalmology specialist,
General neurologist
Clinical Associate Professor, Neurology & Neurological Sciences
Clinical Assistant Professor, Ophthalmology
Heather E. Moss, MD, PhD
Neuro-ophthalmology specialist
Associate Professor of Ophthalmology and of Neurology
Contact us to find out if this trial is right for you.
CONTACT
Mariana Nunez
(650) 497-7846
View on ClinicalTrials.gov